AVM embolization with Onyx.

Unlocking the Brain: A Guide to AVM Embolization with Onyx

Nico Varela monogram
Nico Varela in Health & Wellness October 2026 • 4 min read.

"Discover how cutting-edge techniques like Onyx embolization are revolutionizing the treatment of Arteriovenous Malformations (AVMs), offering hope and improved outcomes for patients."


Cerebral arteriovenous malformations (AVMs) pose significant challenges in the field of neurointerventional surgery. AVMs are abnormal tangles of blood vessels in the brain or on its surface. These tangled vessels disrupt normal blood flow and oxygen circulation, potentially leading to hemorrhages, seizures, or neurological deficits. Managing AVMs requires careful consideration, and while the role of interventional treatments has been debated, embolization has emerged as a valuable tool.

Embolization, often used in conjunction with surgery or radiosurgery, aims to block off the abnormal vessels, reducing the risk of complications and improving overall outcomes. The decision to use embolization depends on the AVM's unique characteristics, such as its size, location, and angioarchitecture – the arrangement of its blood vessels. Factors like the Spetzler-Martin grade, a scale used to assess the risk of surgery, also influence treatment strategies.

While embolization has shown promise, its long-term effectiveness as a standalone treatment is still under investigation. The primary goal of neurointerventional treatment is to safely occlude the feeding arteries that lead to the AVM while preserving the normal venous outflow. By carefully navigating the complex network of blood vessels, specialists aim to minimize complications and maximize the benefits for patients.

AI Search Multiple angles on this topic

Current Evidence

The supplied material does not provide subsection-specific statistics on AVM embolization with Onyx. As a result, no numerical estimate of prevalence, treatment success, complications, or patient impact can be stated here. These measures require directly relevant clinical or epidemiological sources.

Source Scope

The supplied sources address Tufts University’s educational programs and institutional requirements rather than AVM embolization. Tufts states that its graduate programs combine academic excellence, real-world experience, and interdisciplinary study. These materials do not describe accepted AVM treatment methods, Onyx use, or procedural limitations.

Unrelated Technical History

The supplied historical sources concern programming and data manipulation rather than neurovascular treatment. One Stack Overflow discussion from February 4, 2010 asks how to retrieve class information from a Python frame object. Another describes adding controls to an Excel userform frame with VBA, while a third discusses transposing an R data frame.

Onyx Embolization: A Game-Changer for AVM Treatment

AVM embolization with Onyx.

Onyx, also known as Ethylene Vinyl Alcohol (EVOH) copolymer, is a nonadhesive liquid embolic agent transforming how AVMs are treated. Unlike traditional methods, Onyx offers neurointerventionalists greater control and precision during embolization. Its unique properties allow for deliberate injection, penetrating the AVM nidus – the core of the malformation – with remarkable accuracy.

The procedure begins with a detailed cerebral angiogram to map the AVM's intricate network of blood vessels, understanding the AVM’s angioarchitecture. This roadmap guides the neurointerventionalist as they navigate a microcatheter through the feeding arteries, carefully approaching the nidus. Once in position, Onyx is slowly injected, forming a cast within the abnormal vessels and blocking blood flow.

  • Precision Control: Onyx allows for a slow, controlled injection, enabling the physician to monitor its spread and prevent nontarget embolization.
  • Deep Penetration: Its liquid form allows Onyx to seep into the smallest recesses of the AVM nidus, ensuring complete occlusion.
  • Reduced Risk: Unlike some embolic agents, Onyx is nonadhesive, reducing the risk of the catheter becoming stuck within the vessel.
  • Versatility: Onyx can be used as an adjunct to surgery or radiosurgery, or in some cases, as a definitive treatment for certain AVMs.
AI Search Multiple angles on this topic

Research Evidence

No subsection-specific research papers, reviews, or clinical studies were supplied for this topic. The available material therefore cannot support a factual summary of the latest research on AVM embolization with Onyx. Current evidence would need to be assessed from directly relevant medical literature.

Aarhus as an Example

The supplied sources do not document counterarguments, failures, or complications of AVM embolization. They instead describe Aarhus and Aarhus Municipality in Denmark. The sources report 378,361 residents in Aarhus Municipality in 2026, while the Aarhus urban area is reported at 305,227 residents that year.

No Direct Comparison

No sources were supplied that compare Onyx embolization with surgery, radiosurgery, other embolic agents, or observation. A clinically meaningful comparison therefore cannot be made from the available material. Treatment differences, risks, and outcomes require sources specific to cerebral AVMs.

Another embolic agent, N-butyl cyanoacrylate (nBCA) is a synthetic cyanoacrylate-based glue with an Ethiodol carrier. The Ethiodol prevents polymerization when the nBCA comes in contact with ionized solutions. Viscosity of the embolizate can be altered by adjusting the amount of Ethiodol in the mixture. Tantalum powder can also be mixed with the solution to increase the radio-opacity of the solution.

Looking Ahead: The Future of AVM Treatment

Onyx embolization represents a significant advancement in treating AVMs. As technology evolves and techniques refine, we can expect even better outcomes for patients. The key lies in continued research, meticulous planning, and a collaborative approach, ensuring that each patient receives the most appropriate and effective treatment tailored to their unique condition.

AI Search Multiple angles on this topic

Technology Analogy

The supplied sources describe audiovisual KVM extenders rather than AVM embolization. AV Access reports that its 4KEX100-KVM transmits a 4K-at-60Hz HDMI signal over a single Cat6 cable for up to 330 feet, or 100 meters, with zero loss or delay. This technical specification does not provide evidence about Onyx, cerebral blood vessels, or clinical decision-making.

Unrelated Outlook Materials

The supplied future-outlook sources concern Microsoft Outlook and Microsoft Copilot rather than AVM treatment. Microsoft Support explains that Outlook users can share calendars and open shared calendars. The materials do not establish future directions for Onyx embolization or neurointerventional care.

Public Health Context

The supplied broader-context sources focus on the World Health Organization and seasonal influenza. WHO describes itself as a United Nations agency working to promote health, keep the world safe, and serve vulnerable people. Its February 2026 announcement addressed recommendations for influenza vaccine composition for the 2026-2027 Northern Hemisphere season, not AVM embolization.

Patient Impact

No subsection-specific sources were supplied about patients’ experiences, quality of life, recovery, decision-making, or real-world outcomes after AVM embolization with Onyx. Those human impacts should not be inferred from the unrelated materials provided. Direct patient-centered and clinical sources would be needed for a reliable discussion.

What the Onyx figures mean in context

  • 51.4%; 36 months; 3.5%A systematic review reported complete obliteration in 51.4% of patients after an average follow-up of 36 months, and recanalization in 3.5% of patients.[1]

What the Onyx findings add up to

The reported complete-obliteration figure describes an outcome over follow-up, not simply the immediate degree of vessel-volume reduction. These measures capture different stages or aspects of treatment and should not be treated as interchangeable.[1] [2]

The review evidence has limits: most included studies were retrospective and non-randomized, which reduces certainty in its pooled findings.[3]

How the comparisons fit together

The randomized comparison and the single-center comparison both put Onyx alongside NBCA, but they report different measures of volume reduction. The randomized comparison assessed whether cases crossed a reduction threshold, whereas the single-center report compared median devascularization.[2] [4]

The later comparative review likewise found no significant difference in complication rates or technical success, but its significant heterogeneity signals variation among the included comparisons. Its findings therefore do not erase the distinction between individual study results and pooled evidence.[5]

Onyx’s slow injection and limited tendency to adhere to a catheter are procedural contrasts with NBCA, not proof of better clinical outcomes. The findings on volume reduction and comparative outcomes do not establish that a handling difference produces a patient benefit.[4] [6]

What remains unresolved about Onyx embolization

  • How does the risk of hemorrhage change when Onyx obstructs a draining vein early or impairs its drainage? The cited material describes these mechanisms but does not quantify their contribution to complications.[7]

Sources

  1. Long-term complications and outcomes of therapeutic embolization of cerebral arteriovenous malformations: a systematic review (pmc.ncbi.nlm.nih.gov)
  2. Comparison of transarterial n-BCA and Onyx embolization of brain arteriovenous malformations: A single-center 18-year retrospective analysis (pmc.ncbi.nlm.nih.gov)
  3. Preoperative embolisation of brain arteriovenous malformations: a systematic review and meta-analysis (pmc.ncbi.nlm.nih.gov)
  4. A prospective, multicenter, randomized trial of the Onyx liquid embolic system and N-butyl cyanoacrylate embolization of cerebral arteriovenous malformations. Clinical article. (pubmed.ncbi.nlm.nih.gov)
  5. Comparative efficacy and safety of N-butyl cyanoacrylate vs. Onyx in the treatment of arteriovenous malformations: a systematic review and meta-analysis. (pubmed.ncbi.nlm.nih.gov, 2024)
  6. Embolizing intracranial arteriovenous malformations with Onyx: experience at a single center with 250 patients (pmc.ncbi.nlm.nih.gov)
  7. Intra- and post-operative acute hemorrhagic complications of Onyx embolization of brain arteriovenous malformations: A single-center experience (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What exactly are Cerebral Arteriovenous Malformations (AVMs) and what risks do they pose to one's health?

AVMs, or Arteriovenous Malformations, are abnormal tangles of blood vessels that disrupt normal blood flow and oxygen circulation in the brain. This can potentially lead to serious health risks like hemorrhages, seizures, and neurological deficits. AVMs are managed through neurointerventional surgery that may include embolization to block off abnormal vessels and reduce complications.

2

What is Onyx and how is it transforming the treatment of AVMs?

Onyx, also known as Ethylene Vinyl Alcohol (EVOH) copolymer, is a nonadhesive liquid embolic agent used in AVM embolization. It allows neurointerventionalists to have greater control and precision during the procedure. The precision control and deep penetration ensures complete occlusion, reduced risk, and versatility.

3

What role does embolization play in managing AVMs, and how does it relate to surgery or radiosurgery?

Embolization is often used with surgery or radiosurgery to block off abnormal vessels, reducing the risk of complications associated with AVMs. The primary goal is to safely occlude the feeding arteries leading to the AVM while preserving normal venous outflow. The Spetzler-Martin grade is a scale used to assess the risk of surgery and help determine treatment strategies.

4

Can you walk me through the Onyx embolization procedure, detailing how it works to treat AVMs?

During Onyx embolization, a detailed cerebral angiogram is used to map the AVM's network of blood vessels. A microcatheter is then navigated through the feeding arteries to the nidus, where Onyx is slowly injected. This forms a cast within the abnormal vessels, blocking blood flow. Unlike some embolic agents, Onyx is nonadhesive, reducing the risk of the catheter becoming stuck within the vessel.

5

Besides Onyx embolization, are there alternative embolic agents or future treatment options I should be aware of in treating AVMs?

While Onyx embolization offers significant advantages, it's important to note that N-butyl cyanoacrylate (nBCA) is an alternative embolic agent. nBCA is a synthetic cyanoacrylate-based glue with an Ethiodol carrier, this prevents polymerization when the nBCA comes in contact with ionized solutions. The viscosity of the mixture can be adjusted. Continued research and collaboration will help refine techniques and optimize patient outcomes in AVM treatment.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.